{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:26:37Z","timestamp":1794533197223,"version":"4.9.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":217,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000040","name":"American Parkinson's Disease Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.prdoa.2026.100492","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T23:45:16Z","timestamp":1786059916000},"page":"100492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Continuous subcutaneous foslevodopa\/foscarbidopa in advanced Parkinson's disease: A clinical workflow from 50 consecutive patients at a single U.S. center"],"prefix":"10.1016","volume":"15","author":[{"given":"Saar","family":"Anis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Shaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.prdoa.2026.100492_bb0005","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","article-title":"Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial","volume":"21","author":"Soileau","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.prdoa.2026.100492_bb0010","doi-asserted-by":"crossref","DOI":"10.1007\/s40120-026-00948-6","article-title":"Real-world safety and effectiveness of 24-hour Foslevodopa\/Foscarbidopa in Parkinson\u2019s disease: ROSSINI study 6-month interim results","author":"Jost","year":"2026","journal-title":"Neurol Ther."},{"issue":"6","key":"10.1016\/j.prdoa.2026.100492_bb0015","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s00415-026-13879-x","article-title":"Real-world outcomes and early discontinuation of foslevodopa\/foscarbidopa in Parkinson\u2019s disease","volume":"273","author":"Tsuboi","year":"2026","journal-title":"J. Neurol."},{"key":"10.1016\/j.prdoa.2026.100492_bb0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-026-48602-3","article-title":"Foslevodopa-Foscarbidopa subcutaneous infusion in Parkinson\u2019s disease: a cross-cultural\/cross-racial international multicentre comparative tolerability study (CRIM-FOS study)","author":"Metta","year":"2026","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.prdoa.2026.100492_bb0025","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00702-024-02773-3","article-title":"Advanced therapies in Parkinson\u2019s disease: an individualized approach to their indication","volume":"131","author":"Schr\u00f6ter","year":"2024","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.prdoa.2026.100492_bb0030","article-title":"Continuous subcutaneous foslevodopa\/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson\u2019s disease: considerations for initiation and maintenance","volume":"10","author":"Fung","year":"2024","journal-title":"Clin. Park. Relat. Disord."},{"issue":"6","key":"10.1016\/j.prdoa.2026.100492_bb0035","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1007\/s12325-026-03579-3","article-title":"Foslevodopa\/Foscarbidopa subcutaneous infusion safety and efficacy in patients with and without prior deep brain stimulation","volume":"43","author":"Henriksen","year":"2026","journal-title":"Adv. Ther."},{"key":"10.1016\/j.prdoa.2026.100492_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2026.108302","article-title":"Continuous subcutaneous levodopa infusion in advanced Parkinson\u2019s disease patients with subthalamic nucleus deep brain stimulation","volume":"147","author":"De Monte","year":"2026","journal-title":"Parkinsonism Relat. Disord."},{"issue":"12","key":"10.1016\/j.prdoa.2026.100492_bb0045","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/bmjqs-2015-004411","article-title":"SQUIRE 2.0 (standards for QUality improvement reporting excellence): revised publication guidelines from a detailed consensus process","volume":"25","author":"Ogrinc","year":"2016","journal-title":"BMJ Qual. Saf."},{"issue":"7","key":"10.1016\/j.prdoa.2026.100492_bb0050","first-page":"2961","article-title":"Device-aided therapies for advanced Parkinson disease: insights from an international survey","volume":"42","author":"Marsili","year":"2021","journal-title":"Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol."},{"issue":"2","key":"10.1016\/j.prdoa.2026.100492_bb0055","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archneurol.2010.260","article-title":"Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues","volume":"68","author":"Bronstein","year":"2011","journal-title":"Arch. Neurol."},{"issue":"12","key":"10.1016\/j.prdoa.2026.100492_bb0060","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.jagp.2016.08.017","article-title":"Neuropsychiatric complications of Parkinson disease treatments: importance of multidisciplinary care","volume":"24","author":"Taylor","year":"2016","journal-title":"Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry"},{"issue":"3","key":"10.1016\/j.prdoa.2026.100492_bb0065","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/0891988704267466","article-title":"Neuropsychiatric complications of medical and surgical therapies for Parkinson\u2019s disease","volume":"17","author":"Burn","year":"2004","journal-title":"J. Geriatr. Psychiatry Neurol."},{"issue":"10","key":"10.1016\/j.prdoa.2026.100492_bb0070","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00702-024-02807-w","article-title":"Multidisciplinary care in Parkinson\u2019s disease","volume":"131","author":"Weise","year":"2024","journal-title":"J. Neural Transm."},{"issue":"3","key":"10.1016\/j.prdoa.2026.100492_bb0075","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3233\/JPD-202078","article-title":"Recommendations for the organization of multidisciplinary clinical care teams in Parkinson\u2019s disease","volume":"10","author":"Radder","year":"2020","journal-title":"J. Parkinsons Dis."}],"container-title":["Clinical Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112526000721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112526000721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T00:57:23Z","timestamp":1794531443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590112526000721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":15,"alternative-id":["S2590112526000721"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2026.100492","relation":{},"ISSN":["2590-1125"],"issn-type":[{"value":"2590-1125","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Continuous subcutaneous foslevodopa\/foscarbidopa in advanced Parkinson's disease: A clinical workflow from 50 consecutive patients at a single U.S. center","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2026.100492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100492"}}